JP2012525335A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525335A5
JP2012525335A5 JP2012507474A JP2012507474A JP2012525335A5 JP 2012525335 A5 JP2012525335 A5 JP 2012525335A5 JP 2012507474 A JP2012507474 A JP 2012507474A JP 2012507474 A JP2012507474 A JP 2012507474A JP 2012525335 A5 JP2012525335 A5 JP 2012525335A5
Authority
JP
Japan
Prior art keywords
alkyl
piperazin
benzamide
pyridin
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012507474A
Other languages
English (en)
Japanese (ja)
Other versions
JP5741574B2 (ja
JP2012525335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032477 external-priority patent/WO2010126851A1/en
Publication of JP2012525335A publication Critical patent/JP2012525335A/ja
Publication of JP2012525335A5 publication Critical patent/JP2012525335A5/ja
Application granted granted Critical
Publication of JP5741574B2 publication Critical patent/JP5741574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012507474A 2009-04-27 2010-04-27 Cxcr3受容体アンタゴニスト Active JP5741574B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17286909P 2009-04-27 2009-04-27
US61/172,869 2009-04-27
US31735110P 2010-03-25 2010-03-25
US61/317,351 2010-03-25
PCT/US2010/032477 WO2010126851A1 (en) 2009-04-27 2010-04-27 Cxcr3 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2012525335A JP2012525335A (ja) 2012-10-22
JP2012525335A5 true JP2012525335A5 (enExample) 2013-06-20
JP5741574B2 JP5741574B2 (ja) 2015-07-01

Family

ID=42272001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507474A Active JP5741574B2 (ja) 2009-04-27 2010-04-27 Cxcr3受容体アンタゴニスト

Country Status (7)

Country Link
US (1) US8362249B2 (enExample)
EP (1) EP2424858B1 (enExample)
JP (1) JP5741574B2 (enExample)
AR (1) AR076460A1 (enExample)
TW (1) TW201103933A (enExample)
UY (1) UY32574A (enExample)
WO (1) WO2010126851A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
KR101800607B1 (ko) 2012-02-02 2017-11-23 액테리온 파마슈티칼 리미티드 4-(벤조이미다졸-2-일)-티아졸 화합물 및 관련 아자 유도체
KR20150132345A (ko) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac 저해제
WO2014182688A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
WO2014182673A1 (en) * 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
AR096788A1 (es) 2013-07-02 2016-02-03 Bristol Myers Squibb Co Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
JP6330040B2 (ja) 2013-07-22 2018-05-23 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd 1−(ピペラジン−1−イル)−2−([1,2,4]トリアゾール−1−イル)−エタノン誘導体
AR099789A1 (es) * 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
DK3174868T3 (da) 2014-08-01 2021-11-08 Nuevolution As Forbindelser, der er aktive mod bromodomæner
TWI689497B (zh) * 2014-09-04 2020-04-01 南北兄弟藥業投資有限公司 芳雜環類衍生物及其在藥物中的應用
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
PT3245203T (pt) 2015-01-15 2019-02-08 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como modeladores do recetor cxcr3
IL312413B1 (en) 2018-08-29 2025-09-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-enol)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329356T3 (es) * 2002-06-12 2009-11-25 Chemocentryx, Inc. Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias.
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
CA2514940A1 (en) * 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
ES2543714T3 (es) * 2005-06-22 2015-08-21 Chemocentryx, Inc. Compuestos de azaindazol y métodos de uso
US20090030012A1 (en) * 2006-02-23 2009-01-29 Adams Alan D Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
JP5286646B2 (ja) * 2006-04-19 2013-09-11 トヨタ自動車株式会社 スルホン基含有モノマーの重合方法
CN101426774B (zh) * 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
US20090099201A1 (en) * 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト

Similar Documents

Publication Publication Date Title
JP2012525335A5 (enExample)
AU2017261336B2 (en) Modulators of the integrated stress pathway
ES2540996T3 (es) Compuestos de N-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos como inhibidores de tirosina cinasa del receptor de tipo III
US20240307382A1 (en) Modulators of the integrated stress pathway
RU2518089C2 (ru) Производные имидазопиридина в качестве ингибиторов рецепторных тирозинкиназ
CN115003304A (zh) 通过泛素蛋白酶体途径降解btk的双官能化合物
TW202122387A (zh) Mta協同性之prmt5抑制劑
BR112016016289B1 (pt) Heteroaris e usos dos mesmos
AU2019249849A1 (en) BRM targeting compounds and associated methods of use
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
BR112019012957A2 (pt) derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
JP2023545396A (ja) Heliosのピペリジニル低分子分解剤および使用方法
BR112019012993A2 (pt) derivados de benzo-oxazol como imunomoduladores
JP2006524254A5 (enExample)
TW200530217A (en) Amino-benzazoles as P2Y1 receptor inhibitors
WO2015177326A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
BRPI0418082B1 (pt) Derivados de tiazol úteis como antagonistas de receptor de adenosina A2A
JP2012525367A5 (enExample)
CA3211347A1 (en) Indazole based compounds and associated methods of use
JP2020503268A (ja) 選択的hdac1、2阻害剤としてのピペラジン誘導体
EP3237415A1 (en) Tgf receptor antagonists
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
AU2015402778A1 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
JP2018525377A5 (enExample)